NASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis $3.57 +0.04 (+1.13%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$3.56 -0.01 (-0.42%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Larimar Therapeutics Stock (NASDAQ:LRMR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Larimar Therapeutics alerts:Sign Up Key Stats Today's Range$3.27▼$3.8950-Day Range$1.83▼$3.8852-Week Range$1.61▼$9.50Volume4.40 million shsAverage Volume825,111 shsMarket Capitalization$228.59 millionP/E RatioN/ADividend YieldN/APrice Target$18.50Consensus RatingBuy Company Overview Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. Read More Larimar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreLRMR MarketRank™: Larimar Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 645th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Larimar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -2.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Larimar Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.24% of the float of Larimar Therapeutics has been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Larimar Therapeutics has recently decreased by 3.54%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.24% of the float of Larimar Therapeutics has been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Larimar Therapeutics has recently decreased by 3.54%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment0.79 News SentimentLarimar Therapeutics has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Larimar Therapeutics this week, compared to 2 articles on an average week.Search Interest12 people have searched for LRMR on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows27 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Larimar Therapeutics' insider trading history. Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LRMR Stock News HeadlinesLarimar Therapeutics shares drop following $60 million public offeringJuly 30 at 1:24 PM | msn.comLarimar Therapeutics Announces Pricing of Underwritten Public OfferingJuly 29 at 12:02 AM | globenewswire.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.July 31 at 2:00 AM | Priority Gold (Ad)Larimar Therapeutics, Inc. Announces Pricing of $60 Million Public Offering of Common StockJuly 29 at 12:00 AM | quiverquant.comQLarimar Therapeutics Announces Proposed Underwritten Public OfferingJuly 29 at 4:01 PM | globenewswire.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Receives $18.50 Consensus PT from BrokeragesJuly 29 at 2:07 AM | americanbankingnews.comLarimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's AtaxiaJuly 8, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Larimar Therapeutics (LRMR)June 24, 2025 | theglobeandmail.comSee More Headlines LRMR Stock Analysis - Frequently Asked Questions How have LRMR shares performed this year? Larimar Therapeutics' stock was trading at $3.87 on January 1st, 2025. Since then, LRMR shares have decreased by 7.8% and is now trading at $3.57. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) released its quarterly earnings data on Wednesday, April, 30th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.04. Who are Larimar Therapeutics' major shareholders? Top institutional shareholders of Larimar Therapeutics include Assenagon Asset Management S.A. (0.40%), Ethic Inc. (0.10%), CWM LLC (0.05%) and Next Level Private LLC (0.03%). Insiders that own company stock include James E Flynn, Michael Celano, Joseph Truitt and Frank E Thomas. View institutional ownership trends. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Larimar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Larimar Therapeutics investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings4/30/2025Today7/31/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LRMR CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Larimar Therapeutics$18.50 High Price Target$26.00 Low Price Target$10.00 Potential Upside/Downside+418.2%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.60 million Net MarginsN/A Pretax MarginN/A Return on Equity-52.48% Return on Assets-46.08% Debt Debt-to-Equity RatioN/A Current Ratio7.48 Quick Ratio7.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.69 per share Price / Book1.33Miscellaneous Outstanding Shares64,030,000Free Float61,147,000Market Cap$228.59 million OptionableOptionable Beta0.86 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:LRMR) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.